Shares of MannKind surged in early trading, rising 39.28% after the company unveiled a new development program to create a dry powder inhalation (DPI) version of ralinepag in partnership with United Therapeutics Corporation.
Under the firms' expanded license and collaboration agreement, MannKind said it has been working on MNKD-1501, a DPI formulation of ralinepag, for United Therapeutics. The terms of the collaboration make MannKind eligible for up to $35 million in development milestone payments and a 10% royalty on net sales of any eventual product.
The announcement also identifies a $5 million near-term payment as part of the deal framework, offering an immediate cash catalyst in addition to the milestone and royalty upside.
Clinical and commercial context
Investors highlighted the clinical progress behind the program. In March, United Therapeutics reported that its long-term pivotal Phase 3 ADVANCE OUTCOMES study of ralinepag extended-release tablets in pulmonary arterial hypertension achieved its primary endpoint with high statistical significance. That successful Phase 3 readout provides the program with a stronger commercial and scientific backdrop as MannKind advances a DPI formulation.
The companies' collaboration has precedent: an original 2018 agreement led to development and eventual FDA approval of Tyvaso DPI in May 2022. United Therapeutics reported that Tyvaso DPI generated $1.3 billion in revenue in 2025, establishing a commercial benchmark that investors appear to be using to assess MNKD-1501's potential.
Market dynamics and recent history
The timing of the announcement is notable given recent headwinds for MannKind. In February 2026, United Therapeutics launched TreSMI, a soft mist inhaler positioned as a competitor to MannKind’s Tyvaso DPI. That development precipitated a near 40% drop in MannKind's stock earlier this year. Today's collaboration news was interpreted by some market participants as a reorientation of the relationship between the two firms toward cooperation and expansion rather than direct competitive risk.
Broader equity market strength also provided a favorable backdrop for the share move. On the day of the announcement, the S&P 500 gained 1.10%, the Dow Jones Industrial Average rose 1.28%, and the NASDAQ advanced 1.28%, reflecting general risk-on sentiment across major indexes.
Analyst coverage and near-term focus
Analyst coverage ahead of the deal had been mixed. H.C. Wainwright trimmed its price target on MannKind from $11 to $8 while retaining a Buy rating, and Leerink Partners maintained an Outperform rating, indicating differing views on valuation but some underlying optimism about upside potential.
Investor attention is likely to remain elevated in the near term: MannKind is scheduled to release first quarter 2026 financial results on May 6, 2026, after the market close. Combined with the ralinepag DPI news and the immediate $5 million payment, the company now has multiple catalysts that together helped push shares higher during morning trading.
Implications
The announcement reframes the MannKind-United Therapeutics relationship by adding a concrete near-term payment, a clear path to $35 million in development milestones, and a royalty arrangement tied to a drug candidate that has posted a successful Phase 3 readout. Those elements, together with a positive market environment and an upcoming earnings report, created a confluence of factors that drove the sharp intraday share gain.
While the development program advances, the financial upside for MannKind remains linked to the successful progression of MNKD-1501 and any future commercial performance tied to royalties.